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Abstract
Background: Multidisciplinary patient management including a clinical pharmacist shows an improvement in patient
quality use of medicine. Implementation of a clinical pharmacy service represents a significant novel change in practice in
Sri Lanka. Although attitudes of doctors and nurses are an important determinant of successful implementation, there is
no Sri Lankan data about staff attitudes to such changes in clinical practice. This study determines the level of acceptance
and attitudes of doctors and nurses towards the introduction of a ward-based clinical pharmacy service in Sri Lanka.
Methods: This is a descriptive cross-sectional sub-study which determines the acceptance and attitudes of healthcare
staff about the introduction of a clinical pharmacy service to a tertiary care hospital in Sri Lanka. The level of acceptance
of pharmacist’s recommendations regarding drug-related problems (DRPs) was measured. Data regarding attitudes were
collected through a pre-tested self-administered questionnaires distributed to doctors (baseline, N =13, post-intervention
period, N = 12) and nurses (12) worked in professorial medical unit at baseline and post-intervention period.
Results: A total of 274 (272 to doctors and 2 to nurses) recommendations regarding DRPs were made. Eighty three
percent (225/272) and 100% (2/2) of the recommendations were accepted by doctors and nurses, respectively. The rate
of implementation of pharmacist’s recommendations by doctors was 73.5% (200/272) (95% CI 67.9 – 78.7%; P < 0.001).
The response rate of doctors was higher at the post-intervention period (92.3%; 12/13) compared to the baseline
(66.7%; 8/12). At the post-intervention survey 91.6% of doctors were happy to work with competent clinical pharmacists
and accepted the necessity of this service to improve standards of care. The nurses’ rate of response at baseline and
post-intervention surveys were 80.0 and 0.0% respectively. Their perceptions on the role of clinical pharmacist were
negative at baseline survey.
Conclusions: There was high acceptance and implementation of clinical pharmacist’s recommendations regarding
DRPs by the healthcare team. The doctors’ views and attitudes were positive regarding the inclusion of a ward-based
pharmacist to the healthcare team. However there is a need to improve liaison between clinical pharmacist and
nursing staff.
Trial registration: Sri Lanka Clinical Trials Registry SLCTR/2013/029 Date: 13 September 2013; retrospectively registered.
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Background
Medication use is one of the most common types of inter-
ventions in healthcare and it is ubiquitous. Many years
ago, most Western and European countries identified the
positive impact of a clinical pharmacy service in im-
proving quality use of medicines (QUM) which in turn
improves overall patient care [1].
However, collaboration between medical staff and clin-
ical pharmacists in providing patient care is a novel con-
cept in Sri Lanka. At present pharmacists are not a part
of the multidisciplinary healthcare team and their role is
limited to drug dispensing, providing limited medicine
information and compounding within the hospital.
Non-communicable chronic diseases (NCCDs) com-
prise a major group of diseases that necessitate the long
term use of medications. NCCDs are a significant global
health challenge affecting both the developed and devel-
oping world [2, 3]. Sri Lanka is a developing country
with a high burden of NCCDs that in 2012 accounted
for almost one-third of hospital admissions [4].
In many countries hospital treatment of NCCDs utilizes
multidisciplinary teams that include clinical pharmacy
services [5–7]. McAlister, et al. in their systematic review
of randomized controlled trials had revealed that multidis-
ciplinary approaches that included clinical pharmacy ser-
vices in managing patients with heart failure had reduced
mortality and morbidity [6]. Another systematic review
analyzing 126 studies in United States showed a cost
benefit on health outcomes in pharmacist directed
pharmaceutical care services [8].
In order to inform policy makers in Sri Lanka regarding
future developments in health care delivery we conducted
a study to evaluate the implementation, impact, and ac-
ceptability of the introduction of a ward-based clinical
pharmacy service as a novel intervention in a tertiary care
hospital in Sri Lanka [9, 10].
This paper describes the level of acceptance of the
clinical pharmacy service; in the aforementioned primary
study, by the other members of the healthcare team. This
sub-study utilizes the observational data gathered from
the intervention arm of the clinical trial and data gathered
from a separate staff survey. The aims of this sub-study
were to determine the level of acceptance of the clinical
pharmacist’s recommendations to resolve Drug Related
Problems (DRPs) by the healthcare staff, to determine the
quantity and quality of drug information queries directed
to the clinical pharmacist from other staff and to assess
the views and attitudes of the other members of health-
care staff towards the clinical pharmacy service.
Methods
Study design, setting and procedure
We established a controlled clinical trial to assess the ef-
fectiveness of a clinical pharmacy service in improving
QUM in patients with NCCDs. This paper described a
descriptive cross-sectional sub-study of abovementioned
controlled trial under the area of the acceptance and atti-
tudes of healthcare staff on the introduction of a clinical
pharmacy service to a tertiary care hospital in Sri Lanka.
Within the intervention arm acceptance of the clinical
pharmacy service was measured by quantitatively exam-
ining the rate of acceptance of the clinical pharmacist’s
recommendations regarding DRPs by the healthcare
staff and by quantitatively and qualitatively examining
the drug information queries directed to the clinical
pharmacist by the healthcare staff. Staff attitudes to-
wards the acceptance of the clinical pharmacy service
was determined by repeated surveys which conducted
before and after the trial intervention period.
Clinical trial
The clinical trial was conducted over a thirteen months
period (recruitment from March 2013 to September
2013; follow-up from October 2013 to March 2014), in
the University Medical Unit of Colombo North Teaching
Hospital, Sri Lanka; a large tertiary care teaching hos-
pital having 1421 beds with more than 500,000 admis-
sions annually. There was no established ward-based
pharmacy service in the hospital and the existing
hospital pharmacy service was limited to dispensing
and it did not have a formal process for pharmacists’
provision of medication education to patients. The
University Medical Unit consists a female and a male
ward accommodating approximately 55 and 65 patients,
respectively.
Study population
Eligible patients were those with non-communicable
chronic diseases (NCCDs) who needed long-term follow-
up at the medical clinic. Each day the first five eligible
patients in each ward as recorded chronologically in the
admission register were approached by an independent
medical officer to be consented and recruited to the study.
In the first 3 months of the study, patients from the
male ward received the intervention and patients from
the female ward were recruited to the control arm. In
the second 3 months of the study, patients from the
female ward received the intervention and patients from
the male ward were recruited to the control arm. The
control group received usual care which did not include
clinical pharmacist’s input whereas the intervention
group received a clinical pharmacy service in addition to
usual management.
Clinical pharmacist’s interventions The intervention
group patients were interviewed for medication history
on the day of admission and followed up prospectively
during their hospital stay by the clinical pharmacist.
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The pharmacist did medication reconciliation; com-
pared the medications the patient was on prior to ad-
mission with the medications prescribed on the drug
chart after admission and discrepancies were commu-
nicated to the medical team. During the hospital stay,
the pharmacist did a prospective medication review
daily and all the clinically important DRPs were also
discussed with the healthcare team (doctors and nurses)
and appropriate recommendations made. The pharma-
cist also educated patients regarding their medications
and provided medication information to the healthcare
team when needed. The pharmacist took part in the
ward rounds weekly to support multidisciplinary patient
management.
Training received by clinical pharmacist The inter-
vention pharmacist was a B. Pharm graduate and clinical
pharmacy was a subject in her undergraduate curricu-
lum. Before and during the study period the pharmacists
received ward-based teaching from Australian clinical
pharmacy educators and weekly Skype™ case based
conference tutorials were also undertaken with senior
clinical pharmacists from Australia.
Staff survey
The views and general perspectives of healthcare staff
was assessed through a self-administered questionnaire
at baseline (before introducing the clinical pharmacy ser-
vice) and at the end of the trial (post-intervention) to de-
termine any change in the views and attitudes of doctors
and nurses towards the clinical pharmacy service.
This questionnaire was developed and pre-tested in a
pilot study and reviewed by a team of clinical pharma-
cists and consultant physicians prior to the study. The
questionnaire was developed in such a way that it sought
the general perspectives of health staff on how this inte-
grated medicine management related to both patients
and to the healthcare staff. In the questionnaire there
were 17 questions in total. The answers to the first 9
close-ended questions were designed using a five-grade
Likert scale, ranging from “strongly agree”, “agree”, “no
opinion”, “disagree” and “strongly disagree” (Additional
file 1: Table S1 and Additional file 2: Table S3). The other
questions were customized for medical or nursing staff
and addressed specific tasks of the clinical pharmacy ser-
vice provided (Additional file 3: Table S2 and Additional
file 4: Table S4). These questions were answered with a
dichotomized response alternative, “Yes” or “No”. An
independent research assistant distributed the question-
naires among all the healthcare members (consultant
physicians, senior-registrars, registrars, grade medical
officers, intern house officers and nursing staff ) who
worked in the University Medical Unit during the rele-
vant study period were included and the completed
questionnaires were collected in a sealed box kept in the
staff room. Participants were given a participant infor-
mation sheet and in addition they were informed about
the purpose of the survey verbally by the investigator.
An individual consent form was attached with the ques-
tionnaire and it clearly explained the purpose of the sur-
vey and the capability of participants to voluntarily
withhold their consent.
Study outcomes
The study outcomes included level of acceptance of the
pharmacist’s recommendations regarding DRPs, quantity
and nature of drug information queries directed to the
clinical pharmacist by the healthcare staff and the views
and attitudes of the healthcare staff towards clinical
pharmacy service.
The clinical pharmacist identified and classified DRPs
according to the adapted Pharmaceutical Care Network
Europe (PCNE) classification system V5.01 [11]. A subset
of 52% of DRPs were externally validated by Australian
clinical pharmacy team and two consultant physicians in-
volved in the study. The pharmacist’s recommendations
were identified as “Accepted” (the healthcare staff
accepted the pharmacist’s recommendations) and “Not
accepted” (the staff did not agree with the recommen-
dations) interventions. Accepted interventions were
further classified into two categories depending on the
implementation of the accepted recommendation (“Im-
plemented” or “Not implemented”). Implementation of
the recommendation was considered as resolution of
the DRPs.
Details of medication-related queries directed to the
clinical pharmacist from healthcare staff were recorded
on a pre-prepared data collection form.
The attitudes and views of the healthcare staff were
obtained from the self-administered questionnaire as
described under staff survey above.
Data analysis
The data were inputted into SPSS, V.21. Sample propor-
tion tests in Minitab 14 were used to calculate the propor-
tions. P values less than 0.05 (P < 0.05) were considered to
be statistically significant.
Results
361 and 356 patients were recruited to the intervention
and the control arms of the clinical trial, respectively.
Acceptance of recommendations regarding DRPs
In the intervention arm, a total of 274 DRPs were identi-
fied and communicated to the healthcare team (272 to
doctors and 2 to nurses) by the clinical pharmacist along
with the recommendations for resolving them. Different
types of DRPs identified are given in Table 1.
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Eighty three percent (225/272); P < 0.001 of the recom-
mendations made to the doctors were accepted. 73.5%
(200/272); P < 0.001) of the recommendations were im-
plemented; i.e. the medical staff made changes to the
therapeutic regimen (Fig. 1).
All recommendations on drug-drug interactions and
prescription errors were accepted and acted upon
(Table 1). A large number of recommendations (162/
272) were made to prescribers on untreated indications
(i.e. not prescribing a treatment for a particular disease
or condition) (Table 1). Of these, the most frequently
identified (146/162) were non-reconciliation problems.
When there was no documentation or clinically valid
reason for not continuing patient’s chronic medications
they were described as non-reconciled. A total of 72.6%
(106/146) (95% CI 64.6 – 79.7%; P < 0.001) of non-
reconciled DRPs were rectified after discussion between
the prescriber and the clinical pharmacist. Two DRPs
about missing the prescribed drugs on the drug chart
were identified during data collection and were dis-
cussed with nursing staff and resolved.
Drug information queries directed to the clinical pharmacist
A total of 17 medication-related questions were pro-
actively directed to the clinical pharmacist during the
seven months study period. Nine were from doctors, 4
were from nurses and four were from medical students.
The majority of questions from doctors and medical
students were related to the dose and indications of
medicines and available generic substitutions in the
local market. The nature of the queries from nurses’
was about indication, side effects and generic name of a
particular drug (Table 2).
Views and attitudes of the healthcare staff towards
clinical pharmacy service
The rate of response of doctors to the post-intervention
survey was higher than the rate of response to the base-
line survey; 66.7% (8/12) at baseline and 92.3% (12/13)
at post-intervention survey. Out of the 8 doctors who
Table 1 DRPs communicated to doctors and nurses and their resolution rate
Subcategories of DRPs Number of DRPs % resolved
Doctors (N = 272)
Unnecessary therapy/No clinical indication 13 92.3% (12/13)
Untreated indication 162 71.6% (116/162)
Non reconciled medications 146 72.6% (106/146)
Inappropriate duration 4 75.0% (3/4)
Inappropriate dose schedule 11 54.5% (6/11)
Dose too high 3 33.3% (1/3)
Dose too low 1 0.0% (0/1)
Drug-drug interactions 3 100.0% (3/3)
Inappropriate/inadequate monitoring 1 0.0% (0/1)
Prescription error 18 100.0% (18/18)
Manifest side effect, no other cause 7 85.7% (6/7)
More cost-effective drug available 3 66.7% (2/3)
Deterioration/improvement of disease state 3 66.7% (2/3)
Synergistic/preventive drug required and not given 19 63.2% (12/19)
Duplication of therapy 10 90.0% (9/10)
Prescribed drug not available 4 75.0% (3/4)
Avoid contraindications 10 70.0% (7/10)
Nurses (N = 2)
Charting error 2 100.0% (2/2)
Fig. 1 Outcome of pharmacist’s recommendations to doctors
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participated in the baseline survey 5 completed the post-
intervention survey. The survey results showed that all
the consultants participated for the baseline and post-
intervention survey had worked in UK for their post
graduate training.
The views and attitudes of the doctors regarding in-
corporation of clinical pharmacy service to the existing
healthcare system were satisfactory even at the baseline
(Additional file 1: Table S1). At the end of the trial
intervention period, the majority of doctors (11/12)
agreed that the incorporation of a clinical pharmacist
to the existing health care system would be useful and
this collaboration could improve the current QUM
management especially in the public sector hospitals.
Ninety two percent (11/12) of doctors would be happy
to receive the services from a competent clinical
pharmacist. Sixty seven percent (8/12) of doctors ac-
cepted that the pharmacist could advise doctors and
nurses regarding the issues related to medications. One
(8.0%) doctor disagreed with that statement and 25%
(3/12) did not express any view. The majority (91.7%)
of doctors agreed that adding a pharmacist to the team
is not a waste of money and is necessary to the current
healthcare system. Sixty seven percent (8/12) of doctors
agreed that pharmacists can play an important role in
tailoring drug therapy for individual patients. Ninety
two percent (11/12) of doctors acknowledged that
pharmacist’s contribution is important in improving
patients’ medication adherence. The majority of doctors
(75.0%) had the opinion that the patients’ awareness
about drugs and changes to the patients’ drug therapy
was poor.
Doctors views related to the role played by the
pharmacist was positive even at the baseline and had
improved further following the intervention period
(Additional file 3: Table S2). In post-intervention survey
more than 75% of doctors agreed that pharmacists can
alert the prescriber on adverse drug reactions, interac-
tions and allergies. All the doctors believed that the
pharmacist can act as a drug information source to pa-
tients and carers. More than 50% of doctors agreed that
pharmacists can play an important role in assuring the
safety and appropriateness of prescribed medicines.
The response rate of nursing staff was 80.0% (12/15)
at the baseline. However the nursing staff did not con-
sent to participate in the post-intervention survey. The
perspectives of nursing staff at the baseline were nega-
tive; 58.3% (7/12) stated that there is no need of a
ward-based clinical pharmacy service and 66.7% (8/12)
were not happy to welcome the pharmacy service
(Additional file 2: Table S3). The majority of the nurs-
ing staff did not agree that a clinical pharmacist could
make a useful contribution for patient management
(Additional file 4: Table S4).
Discussion
Clinical pharmacy is a health science discipline which
delivers patient-oriented pharmaceutical care, with an
aim of improving safe and rational use of medicines
[12]. Studies conducted in different parts of the world
Table 2 Medication-related queries directed to the clinical pharmacist
Drug Query Directed by
Ferrup (Brand of ferrous sulphate) What are the dosage forms available in Sri Lanka? Intern house officers
Folic acid What are the strengths of the tablets available? Intern house officers
Tetracycline What are the possible side effects? Nurse
Ceftriaxone What is the best cephalosporin to replace ceftriaxone when therapy is
changed to oral administration?
Intern house officers
Ferrous sulphate What is the usual frequency? Intern house officers
Rifaximin What is the indication? Medical student
Ciprofloxacin What is the strength of the oral formulation? Intern house officers
Amifru (Brand of frusemide + amiloride) What is the generic equivalent? Intern house officers
Co-trimoxazole What is the dose? Intern house officers
Erythromycin Can this be prescribed for children? Medical student
Stematil (Prochlrperazine) What is the generic equivalent? Nurse
Aspirin What is the efficacy of enteric coated aspirin in preventing gastric irritation Medical student
Carticare (Brand of glucosamine) What is the generic equivalent? Intern house officers
Paraffin cream What is the indication? Nurse
Imuran (Brand of azathioprine) What is the generic equivalent? Nurse
Insulin How to use an insulin pen Medical student
Tamiflu (Brand of oseltamivir) What is the generic equivalent? Intern house officers
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have shown the benefits of a clinical pharmacy service in
terms of reducing negative outcomes of DRPs and im-
proving patient safety [13, 14], improving appropriate-
ness of prescriptions [15, 16] and reducing the impact of
healthcare expenditure [17].
In Sri Lankan hospitals clinical pharmacy service does
not exist and this is a completely new concept to the
existing healthcare environment. This is the first inter-
ventional study carried out in Sri Lanka evaluating the
acceptance of the recommendations made by a clinical
pharmacist by other members of the healthcare team.
This study showed that the addition of a clinical
pharmacist to the study setting was positively received
by the attending doctors. An acceptance rate of 83.0% of
pharmacists’ recommendations regarding DRPs by doc-
tors was comparable to developed world settings where
acceptance rates range between 63 and 90% [18–20].
The implementation of the pharmacist’s recommenda-
tions of 73.5% was comparable to a study done in
Sweden by Gillespie, et al. where 75% of the pharmacists’
suggestions were implemented [21]. The acceptance of
pharmacist’s recommendations regarding DRPs shows
that the physician-pharmacist inter-professional relation-
ship was successfully established in the busy tertiary care
hospital where the study was carried out.
The attitudes and views of doctors ranging from
specialist physicians, senior registrars and registrars to
intern medical officers about the incorporation of clin-
ical pharmacy service and its benefits were positive. A
great majority (91.7%) of doctors agreed that adding a
pharmacist to the team would be cost effective and is
vital to the current healthcare system. Physicians’ per-
spectives on collaborative work with a clinical pharma-
cist had been studied widely in many other countries
[22–25]. Gillespie, et al. reported that 95% of physicians
were satisfied with the incorporation of a clinical phar-
macy service to the university hospital in Uppsala in
Sweden, which was a new introduction to that setting
at that time [22].
However the pharmacist-nurse interaction on team-
based patient management had not been explored ex-
tensively [22, 26]. In this study, even though a wide
proportion of doctors acknowledged the importance of
clinical pharmacy service, the response received from
the nursing staff was negative as assessed at the base-
line. Lack of awareness and knowledge about the im-
portance of clinical pharmacy service in improving
QUM and potential benefits to patient care could be
the likely reason for this negative response. The survey
results showed that none of participated nurses had
been worked with a clinical pharmacist in overseas or
any private sector hospital. Another survey conducted
in Sri Lanka to evaluate the perception of healthcare
staff towards the addition of clinical pharmacy service
had showed similar findings. According to the results
of that survey, 60% of medical staff believed that the
incorporation of clinical pharmacists would improve
the rational prescribing of medications [27]. However
similar to the results of our study the responses of
nurses were mostly negative; only 10% appreciated the
usefulness of clinical pharmacy service [27]. A study
from Pakistan published in 2012, showed a negative
perception from nurses towards the role of pharmacist
in Pakistan’s healthcare setting [28].
Data from our study emphasizes that there is a need
to improve awareness and build trust and relationships
with nursing staff in order to demonstrate the potential
benefits and promote a clinical pharmacy service in Sri
Lankan hospitals.
The foundation for building an efficient team is to
encourage learning as a team. Training students on
team care at undergraduate and postgraduate levels is
likely to improve the awareness of skills and strengths
of each category of professionals and help to overcome
the barriers for implementation of the clinical phar-
macy service [29, 30].
Results of this study demonstrated that the clinical
pharmacy service is well accepted and utilized by the
medical staff in the tertiary care hospital indicating that
there is a significant opportunity for the Sri Lankan
clinical pharmacist to make a valuable contribution to
enhance the QUM. It also demonstrated that a signifi-
cant number of DRPs could be identified and acted
upon in a manner consistent with best practice multi-
disciplinary healthcare teams. As in other countries it
is reasonable to expect that this will result in improved
health outcomes for patients and reduced costs for
health system. Thus, our study provides evidence to
support health policy change in order to introduce
clinical pharmacy service to the healthcare system in
Sri Lanka and the other low and middle-income coun-
tries (LMICs).
Strengths and limitations
The study was undertaken in a tertiary level teaching
hospital with strong support from lead clinicians. This
level of support may not be available in smaller hospitals
in the country. Therefore, the results on the acceptance
of the pharmacist recommendations by the doctors to
resolve DRPs are likely to be generalizable primarily to
tertiary hospitals. Tertiary hospitals are a logical place to
start as they provide higher exposure of health
professionals-in-training to pharmacists being included
in multidisciplinary care, which will eventually facilitate
expansion to smaller hospitals.
In a study of this duration it is inevitable that there
will be turnover of medical staff within the two hospital
wards where the study was carried out. The average
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number of doctors working in both wards was around
12. Thus we were able to offer the survey to a significant
proportion of doctors in the clinical team. The numbers
of doctors who participated at baseline and after inter-
vention changed mainly because of a change in intern
medical officers as they completed their intern period
during the study. While this is a limitation in compari-
son of results it is unlikely that the prior beliefs of the
doctors had changed. In addition the continued ac-
ceptance of pharmacist recommendations supports the
survey observations.
Even though the nurses withdrew from the post-
intervention survey, they actually did not withdraw
from the clinical trial. As we mentioned the nurses re-
fused to give the consent for participation in the post-
intervention staff survey due to a trade union issue.
This trade union issue was about the nurses being sur-
veyed and being asked to express their views and not
about the pharmacy intervention. Although desirable,
within that context it was not possible to perform any
kind of in-depth interviews, focus groups or similar
qualitative methods with the nursing staff to explore
the reasons for their reluctance to collaborate in this
component of our study. While the second survey of
nursing staff could not be undertaken the 25% of the
medication related questions generated by nurses was
evidence of nurses acceptance of the trial.
Eventhough all the doctors and nurses participated
in the staff survey the number was small. This limits
the generalizability of the results generated from the
staff survey.
Conclusions
There was high acceptance of clinical pharmacist’s rec-
ommendations regarding DRPs by the other members
of the healthcare team and the majority of the DRPs
were resolved through this collaboration. The doctors’
views and attitudes were positive regarding the inclu-
sion of a ward-based pharmacist to the healthcare team
and they recognized that this collaboration improves
QUM in patients. However there is a need to improve
liaison between clinical pharmacist and nursing staff.
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